EUVIMEDEUVIMED entdecken
Crossref

The use of blue dye alone for sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initially node-positive breast cancer

Francisco Pimentel Cavalcante, Felipe Pereira Zerwes, Alessandra Borba Anton Souza, Patrícia Klarmann Ziegelmann, Ryane Alcantara, Amanda Cardoso, André Mattar, Eduardo Camargo Millen, Antonio Luiz Frasson

European Journal of Surgical Oncology · 2024

DOI: 10.1016/j.ejso.2024.107967 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2024. Verfasst von Francisco Pimentel Cavalcante und 8 weiteren Autor:innen. Beteiligte Einrichtung: Breast Surgery Department, Fortaleza General Hospital, Fortaleza, Ceará, Brazil. Electronic address: fpimentelcavalcante@gmail.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Sentinel Lymph Node. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: False-negative sentinel lymph node biopsy (SLNB) rates following neoadjuvant chemotherapy (NACT) in initially node-positive (cN1/2) breast cancer patients are high, but decrease when lymph nodes are clipped, ≥3 sentinel lymph nodes (SLN) are removed or dual-tracer localization (radioisotope and blue dye) is used. Radiotracer, however, is often unavailable and outcomes with blue dye alone are unknown. MATERIALS AND METHODS: Initially cT1-4, cN1/2 patients treated with NACT in 2013-2023 who underwent SLNB using blue dye alone were evaluated regarding SLN identification, axillary recurrence, disease-free and overall survival rates. RESULTS: Of 119 patients included, 19 remained cN1/2 after NACT. SLNB was performed using blue dye alone in 100 ycN0 cases (84%), with an identification rate of 96%. The SLN was negative in 70/119 cases (i.e. 59% avoided axillary dissection). The number of SLN detected was ≥3 in 55/70 cases (78%) (median 3.1; 1-6). Median age was 49 years (25-84). Most were T2 (n = 40, 57.1%), N1 (n = 64, 91.4%). Predominant subtypes were ERBB2 (52.9%) and triple-negative (20%). No axillary recurrence occurred over a median 36-month period. Five-year disease-free and overall survival were, respectively, 85.9% (95%CI: 74-99.8) and 96.3% (95%CI: 89.4-100). The ERBB2 subtype (1.99, 95%CI: 1.02-3.85, p = 0.04) and N1 lymph node status (2.58, 95%CI: 1.54-9.10, p = 0.03) were associated with a greater likelihood of undergoing SLNB alone without axillary dissection. CONCLUSIONS: SLNB with blue dye alone following NACT in initially cN1/2 patients avoided axillary dissection in almost 60% of cases, with no recurrences during the period evaluated. Longer follow-up studies are necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsSentinel Lymph NodeHumansMiddle AgedFemaleSentinel Lymph Node BiopsyNeoadjuvant TherapyLymphatic MetastasisLymph Node ExcisionLymph NodesAxilla

Stichwörter der Autor:innen

Axillary recurrenceBlue dye aloneBreast cancerNeoadjuvant chemotherapyNeoadjuvant treatmentSentinel lymph node biopsy

Autor:innen und Institutionen

  • Breast Surgery Department, Fortaleza General Hospital, Fortaleza, Ceará, Brazil. Electronic address: fpimentelcavalcante@gmail.com.
  • Breast Surgery Department, Pontificia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Rio Grande do Sul, Brazil. Electronic address: zerwes@hotmail.com.
  • Breast Surgery Department, Pontificia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Rio Grande do Sul, Brazil. Electronic address: alessandra.masto@gmail.com.
  • Department of Statistics and Postgraduate Program in Epidemiology, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Rio Grande do Sul, Brazil. Electronic address: patricia.ziegelmann@ufrgs.br.
  • Breast Surgery Department, Fortaleza General Hospital, Fortaleza, Ceará, Brazil. Electronic address: draryaneoliveira@gmail.com.
  • Breast Surgery Department, Fortaleza General Hospital, Fortaleza, Ceará, Brazil. Electronic address: amanda_lcardoso@hotmail.com.

Zitieren

APA

Cavalcante, F. P., Zerwes, F. P., Souza, A. B. A., Ziegelmann, P. K., Alcantara, R., Cardoso, A., Mattar, A., Millen, E. C., & Frasson, A. L. (2024). The use of blue dye alone for sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initially node-positive breast cancer. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2024.107967

Vancouver

Cavalcante FP, Zerwes FP, Souza ABA, Ziegelmann PK, Alcantara R, Cardoso A, et al. The use of blue dye alone for sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initially node-positive breast cancer. European Journal of Surgical Oncology. 2024. doi:10.1016/j.ejso.2024.107967

BibTeX
@article{Cavalcante2024,
  author = {Cavalcante, Francisco Pimentel and Zerwes, Felipe Pereira and Souza, Alessandra Borba Anton and Ziegelmann, Patrícia Klarmann and Alcantara, Ryane and Cardoso, Amanda and Mattar, André and Millen, Eduardo Camargo and Frasson, Antonio Luiz},
  title = {The use of blue dye alone for sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initially node-positive breast cancer},
  journal = {European Journal of Surgical Oncology},
  year = {2024},
  doi = {10.1016/j.ejso.2024.107967}
}
Kostenlos starten →